Ocular Therapeutix (OCUL) PT Raised to $15 at Piper Sandler
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts OCUL Hot Sheet
Price: $6.50 -1.66%
Rating Summary:
21 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
21 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Piper Sandler analyst Joseph Catanzaro raised the price target on Ocular Therapeutix (NASDAQ: OCUL) to $15.00 (from $10.00) while maintaining a Overweight rating.
You May Also Be Interested In
- H.C. Wainwright Reiterates Buy Rating on Ocular Therapeutix (OCUL)
- Pinnacle Financial Partners (PNFP) PT Raised to $115 at DA Davidson
- Tango Therapeutics Inc. (TNGX) PT Raised to $55 at Stifel
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
